Jun 16, 2026 08:02AM
Jun 16, 2026 08:02AM
Jun 1, 2026 08:47AM
Jun 1, 2026 08:46AM
May 26, 2026 07:03AM
May 26, 2026 07:00AM
Dec 19, 2025 08:05AM Outlook Therapeutics reports $62.4 million loss for fiscal 2025
Dec 19, 2025 08:05AM
Nov 13, 2025 08:31AM
Nov 13, 2025 08:30AM
Aug 14, 2025 08:05AM
Jun 13, 2025 06:53AM
May 15, 2025 04:01PM
Apr 9, 2025 07:21AM Guggenheim Reiterates Buy Rating on Outlook Therapeutics Incs. (OTLK)
Apr 8, 2025 05:02PM
Apr 8, 2025 08:45AM
Apr 8, 2025 08:45AM
Jan 23, 2024 08:47AM
Jan 23, 2024 08:00AM
Dec 22, 2023 08:05AM
Dec 6, 2023 08:05AM Outlook Therapeutics (OTLK) Announces Strategic Organizational Realignment
Dec 6, 2023 08:05AM
Nov 27, 2023 08:05AM
Nov 27, 2023 08:05AM
Nov 14, 2023 08:05AM
Nov 2, 2023 08:05AM
Nov 2, 2023 08:05AM
Nov 1, 2023 08:05AM Outlook Therapeutics® to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (INI) Conference
Nov 1, 2023 08:05AM
Sep 29, 2023 08:05AM
Sep 29, 2023 08:05AM
Sep 21, 2023 08:05AM
Sep 5, 2023 08:05AM
Aug 30, 2023 09:22AM
Aug 30, 2023 06:00AM Outlook Therapeutics (OTLK) Receives CRL for ONS-5010
Aug 30, 2023 06:00AM
Aug 14, 2023 08:05AM
Aug 1, 2023 08:45AM
May 15, 2023 08:05AM
Apr 27, 2023 08:05AM
Mar 13, 2023 07:00AM
Feb 14, 2023 08:05AM Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2023 and Provides Corporate Update
Feb 7, 2023 08:05AM
Feb 6, 2023 07:28AM
Jan 19, 2023 08:05AM
Jan 9, 2023 08:05AM
Dec 29, 2022 09:07AM
Dec 29, 2022 09:05AM
Dec 23, 2022 09:00AM Outlook Therapeutics® Enters Definitive Agreement for $31.8 Million Unsecured Convertible Promissory Note
Dec 23, 2022 06:01AM

15,464 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All